PALI - Palisade Bio - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

PALI is currently covered by 2 analysts with an average price target of $-0.4. This is a potential upside of $-1.1 (-157.14%) from yesterday's end of day stock price of $0.7.

Palisade Bio's activity chart (see below) currently has 2 price targets and 6 ratings on display. The stock rating distribution of PALI is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 66.67% with an average time for these price targets to be met of 55 days.

Highest price target for PALI is $8, Lowest price target is $8, average price target is $8.

Most recent stock forecast was given by NAZ RAHMAN from MAXIM GROUP on 13-Nov-2024. First documented stock forecast 02-Feb-2022.

Best performing analysts who are covering PALI - Palisade Bio:

Aydin Huseynov Naz Rahman

Currently out of the existing stock ratings of PALI, 4 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$8

$7 (700.00%)

$22.5

6 months 26 days ago
(13-Nov-2024)

1/3 (33.33%)

$5.8 (263.64%)

1

Buy

$16

$15 (1500.00%)

$25

2 years 23 days ago
(16-May-2023)

3/3 (100%)

$-8 (-33.33%)

109

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is PALI (Palisade Bio) average time for price targets to be met?

On average it took 55 days on average for the stock forecasts to be realized with a an average price target met ratio 66.67

Which analyst has the current highest performing score on PALI (Palisade Bio) with a proven track record?

AYDIN HUSEYNOV

Which analyst has the current lower performing score on PALI (Palisade Bio) with a proven track record?

NAZ RAHMAN

Which analyst has the most public recommendations on PALI (Palisade Bio)?

Aydin Huseynov works at LADENBURG and has 1 price targets and 2 ratings on PALI

Which analyst is the currently most bullish on PALI (Palisade Bio)?

Aydin Huseynov with highest potential upside - $15

Which analyst is the currently most reserved on PALI (Palisade Bio)?

Naz Rahman with lowest potential downside - $7

Palisade Bio in the News

Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to give an oral presentation at the 3rd Annual...

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability of PALI-2108 No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed to date Screening for Phase 1b UC cohort ongoing;...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?